- Home
- ALLO vs FSSL Comparison
ALLO vs FSSL Comparison
Compare ALLO & FSSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALLO | FSSL |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.4M | 885.2M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALLO | FSSL |
|---|---|---|
| Price | $2.17 | $11.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $8.35 | N/A |
| AVG Volume (30 Days) | ★ 6.1M | 287.4K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 15.05% |
| EPS Growth | ★ 34.09 | N/A |
| EPS | N/A | ★ 1.16 |
| Revenue | N/A | ★ $203,111,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $142,416.42 | N/A |
| P/E Ratio | ★ N/A | $10.16 |
| Revenue Growth | N/A | ★ 5.41 |
| 52 Week Low | $0.99 | $11.13 |
| 52 Week High | $4.46 | $14.49 |
Technical Indicators
Market Signals| Indicator | ALLO | FSSL |
|---|---|---|
| Relative Strength Index (RSI) | 48.92 | 46.25 |
| Support Level | $2.12 | $11.44 |
| Resistance Level | $2.71 | $12.75 |
| Average True Range (ATR) | 0.14 | 0.20 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 57.27 | 70.83 |
Price Performance
Historical ComparisonAbout ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
About FSSL FS Specialty
FS Specialty Lending Fund is a United States-based externally managed, non-diversified, closed-end management investment company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation by investing primarily in private and public credit in a broad set of industries, sectors, and sub-sectors. Its investment policy is to invest primarily in a portfolio of secured and unsecured floating and fixed rate loans, bonds, and other types of credit instruments, which, under normal circumstances, will represent at least eighty percent of the Company's total assets.